Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.

"The authors declare that there is no conflict of interest."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from National Natural Science Foundation of China (82373340), ‘Soaring’ Program of the Shanghai Anti-Cancer Association (SACA-AX202209), Beijing Science and Technology Innovation Medical Development Foundation (KC2022-ZZ-0091-4), and CSCO-Pierre Fabre Oncology Research Foundation (Y-pierrefabre202102-0002)."

"This is a retrospective multicenter study, comprising all HER2+ MBC patients who received PyroHC treatment at five medical institutions, including the Fudan University Shanghai Cancer Center, San Huan Cancer Hospital, the Cancer Center of Sun Yat-sen University, West China Hospital of Sichuan University, and Tumor Hospital of the Chinese Academy of Medical Sciences, from June 2017 to January 2023. All investigations were conducted in accordance with the Declaration of Helsinki. The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology statement (Supplemental File 1). Our study has been registered on clinicaltrials.gov (NCT 05839288)."